

Trusted by pharmaceutical companies in more clinical trials than any other brand, the PARI LC PLUS® and LC® Sprint reusable nebulizers combine small, consistent particles and fast treatments for targeted drug delivery to the lungs. PARI nebulizers provide efficient aerosol therapy to help improve quality of life for patients of all ages.

THE CLINICAL CHOICE



PARI Reusable Nebulizers were used in the following clinical trials to prove safety and efficacy:

Pulmicort Respules® -AstraZeneca
Perforomist™, Accuneb®, and Duoneb® -Dey
Pulmozyme® -Genentech
TOBI® -Novartis
Xopenex® and Brovana® -Sunovion

Configurations			
	Part #	HCPCS #	
PARI LC Sprint	023F35	A7005	
PARI LC PLUS	022F81	A7005	


Performance with PARI LC Sprint ¹		
Total Output Rate	500 mg/min	
MMD (Mass Median Diameter)	3.5 µm	
%RF (Mass Percentage <5 μ)	68%	
Average Treatment Time	~5 minutes	

Performance with PARI LC PLUS ¹		
Total Output Rate	440 mg/min	
MMD (Mass Median Diameter)	3.8 µm	
%RF (Mass Percentage <5 μ)	65%	
Average Treatment Time	6-7 minutes	


¹ Tested with a 1.2 bar compressor. Measured with Malvern MasterSizer X at 50% relative humidity, 0.9% NaCl solution, inspiratory flow 20 liters/minute, continuous nebulization, 23° C, fill volume 2.5 ml.


THE **DIFFERENCE** IS IN THE **DELIVERY**

Both PARI LC PLUS and LC Sprint deliver more drug in less time compared to Sidestream® Plus.²



The PARI LC Sprint delivers more drug in significantly less time compared to traditional nebulizers.³







² Weigand, et al. Using RDDR to Compare Delivery Efficiency of Three Commercially Available Breath-Enhanced Nebulizers with Budesonide. CHEST October 2008

³ N.H. Tiffin et al. Comparison of Nebulized Drug Delivery Times of Four Nebulizers. Canadian Journal of Respiratory Therapy 2007 43.2; 43

[†]Trademarks are the property of their respective companies.